Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes
Abstract Aims Left ventricular hypertrophy (LVH) has been associated with an increased risk of cardiovascular (CV) disease and linked to increased morbidity and mortality. In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), hypertension is common, and patients with these co‐morb...
Saved in:
| Main Authors: | Gerasimos Filippatos, Stefan D. Anker, George L. Bakris, Peter Rossing, Luis M. Ruilope, Andrew J.S. Coats, Stephan vonHaehling, Piotr Ponikowski, Giuseppe M.C. Rosano, Meike Brinker, Alfredo E. Farjat, Luke Roberts, Bertram Pitt, the FIDELIO‐DKD and FIGARO‐DKD investigators |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.14962 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials
by: George L Bakris, et al.
Published: (2024-03-01) -
WCN25-288 EFFECT OF FINERENONE TREATMENT DISCONTINUATION ON KIDNEY AND CV OUTCOMES IN PATIENTS WITH CKD AND T2D: A FIDELITY SUBANALYSIS
by: Stefan Anker, et al.
Published: (2025-02-01) -
Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study
by: Yu Li, et al.
Published: (2025-07-01) -
Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China
by: Jingying Zhou, et al.
Published: (2024-12-01) -
Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study
by: Guangting Cong, et al.
Published: (2025-08-01)